Cargando…
Thrombopoietin Receptor Agonists for Thrombocytopenia Secondary to HER2-Targeted Antibody Drug Conjugates
Trastuzumab emtansine and trastuzumab deruxtecan are widely used in breast cancer and other solid tumor malignancies. Thrombocytopenia is a common adverse event associated with the use of these agents that can lead to a treatment delay, reduction in dose intensity, and discontinuation. The role of t...
Autores principales: | , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Oxford University Press
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10485295/ https://www.ncbi.nlm.nih.gov/pubmed/37335880 http://dx.doi.org/10.1093/oncolo/oyad185 |
_version_ | 1785102753780989952 |
---|---|
author | Rainone, Michael Kasparian, Saro Nguyen, Tina Talwar, Neel Yuan, Yuan Mei, Matthew Mortimer, Joanne E Waisman, James R Patel, Niki Pullarkat, Vinod |
author_facet | Rainone, Michael Kasparian, Saro Nguyen, Tina Talwar, Neel Yuan, Yuan Mei, Matthew Mortimer, Joanne E Waisman, James R Patel, Niki Pullarkat, Vinod |
author_sort | Rainone, Michael |
collection | PubMed |
description | Trastuzumab emtansine and trastuzumab deruxtecan are widely used in breast cancer and other solid tumor malignancies. Thrombocytopenia is a common adverse event associated with the use of these agents that can lead to a treatment delay, reduction in dose intensity, and discontinuation. The role of thrombopoietin receptor agonists (TPO-RA) remains unknown in this setting. We report a case series of 6 individuals with breast cancer that experienced dose-reductions and therapy delays due to thrombocytopenia secondary to trastuzumab emtansine or trastuzumab deruxtecan therapy and received intervention with TPO-RA. All 6 were able to resume therapy with TPO-RA support. |
format | Online Article Text |
id | pubmed-10485295 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2023 |
publisher | Oxford University Press |
record_format | MEDLINE/PubMed |
spelling | pubmed-104852952023-09-09 Thrombopoietin Receptor Agonists for Thrombocytopenia Secondary to HER2-Targeted Antibody Drug Conjugates Rainone, Michael Kasparian, Saro Nguyen, Tina Talwar, Neel Yuan, Yuan Mei, Matthew Mortimer, Joanne E Waisman, James R Patel, Niki Pullarkat, Vinod Oncologist Brief Communication Trastuzumab emtansine and trastuzumab deruxtecan are widely used in breast cancer and other solid tumor malignancies. Thrombocytopenia is a common adverse event associated with the use of these agents that can lead to a treatment delay, reduction in dose intensity, and discontinuation. The role of thrombopoietin receptor agonists (TPO-RA) remains unknown in this setting. We report a case series of 6 individuals with breast cancer that experienced dose-reductions and therapy delays due to thrombocytopenia secondary to trastuzumab emtansine or trastuzumab deruxtecan therapy and received intervention with TPO-RA. All 6 were able to resume therapy with TPO-RA support. Oxford University Press 2023-06-19 /pmc/articles/PMC10485295/ /pubmed/37335880 http://dx.doi.org/10.1093/oncolo/oyad185 Text en © The Author(s) 2023. Published by Oxford University Press. https://creativecommons.org/licenses/by/4.0/This is an Open Access article distributed under the terms of the Creative Commons Attribution License (https://creativecommons.org/licenses/by/4.0/), which permits unrestricted reuse, distribution, and reproduction in any medium, provided the original work is properly cited. |
spellingShingle | Brief Communication Rainone, Michael Kasparian, Saro Nguyen, Tina Talwar, Neel Yuan, Yuan Mei, Matthew Mortimer, Joanne E Waisman, James R Patel, Niki Pullarkat, Vinod Thrombopoietin Receptor Agonists for Thrombocytopenia Secondary to HER2-Targeted Antibody Drug Conjugates |
title | Thrombopoietin Receptor Agonists for Thrombocytopenia Secondary to HER2-Targeted Antibody Drug Conjugates |
title_full | Thrombopoietin Receptor Agonists for Thrombocytopenia Secondary to HER2-Targeted Antibody Drug Conjugates |
title_fullStr | Thrombopoietin Receptor Agonists for Thrombocytopenia Secondary to HER2-Targeted Antibody Drug Conjugates |
title_full_unstemmed | Thrombopoietin Receptor Agonists for Thrombocytopenia Secondary to HER2-Targeted Antibody Drug Conjugates |
title_short | Thrombopoietin Receptor Agonists for Thrombocytopenia Secondary to HER2-Targeted Antibody Drug Conjugates |
title_sort | thrombopoietin receptor agonists for thrombocytopenia secondary to her2-targeted antibody drug conjugates |
topic | Brief Communication |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10485295/ https://www.ncbi.nlm.nih.gov/pubmed/37335880 http://dx.doi.org/10.1093/oncolo/oyad185 |
work_keys_str_mv | AT rainonemichael thrombopoietinreceptoragonistsforthrombocytopeniasecondarytoher2targetedantibodydrugconjugates AT kaspariansaro thrombopoietinreceptoragonistsforthrombocytopeniasecondarytoher2targetedantibodydrugconjugates AT nguyentina thrombopoietinreceptoragonistsforthrombocytopeniasecondarytoher2targetedantibodydrugconjugates AT talwarneel thrombopoietinreceptoragonistsforthrombocytopeniasecondarytoher2targetedantibodydrugconjugates AT yuanyuan thrombopoietinreceptoragonistsforthrombocytopeniasecondarytoher2targetedantibodydrugconjugates AT meimatthew thrombopoietinreceptoragonistsforthrombocytopeniasecondarytoher2targetedantibodydrugconjugates AT mortimerjoannee thrombopoietinreceptoragonistsforthrombocytopeniasecondarytoher2targetedantibodydrugconjugates AT waismanjamesr thrombopoietinreceptoragonistsforthrombocytopeniasecondarytoher2targetedantibodydrugconjugates AT patelniki thrombopoietinreceptoragonistsforthrombocytopeniasecondarytoher2targetedantibodydrugconjugates AT pullarkatvinod thrombopoietinreceptoragonistsforthrombocytopeniasecondarytoher2targetedantibodydrugconjugates |